vopemed Secures $2.29M CAD Pre-Seed Funding to Redefine Surgical Visualization with AI
vopemed is developing Claris, an AI-driven image enhancement software designed to improve the clarity of laparoscopic and robotic-assisted procedure video feeds in real-time, leading to safer surgeries.
"This funding validates the need for enhanced surgical visualization and reinforces our mission to bring AI-powered image enhancement into every operating room," said
"We are excited to support vopemed as they bring AI-driven image enhancement to surgery," said
"Clear visualization is critical for precise surgical decisions, especially in minimally invasive procedures. AI-driven image enhancement like Claris could be a game-changer in improving efficiency and patient outcomes," said Dr.
The pre-seed round was led by Genson Capital Inc., which invested
With the funds secured, vopemed will expand R&D, refine its software for broader clinical applications, and strengthen partnerships with hospitals and surgical teams. The company is also preparing for clinical validation studies to further demonstrate Claris' impact in real-world settings.
About vopemed
vopemed is a MedTech startup dedicated to enhancing surgical vision with AI-powered image clarification technology. Its flagship product, Claris, integrates seamlessly with existing surgical systems to provide real-time, high-clarity imaging, reducing visual obstructions and improving visualization in minimally invasive surgery. The company is committed to redefining surgery by equipping surgical teams with cutting-edge tools for safer, more efficient procedures.
View original content to download multimedia:https://www.prnewswire.com/news-releases/vopemed-secures-2-29m-cad-pre-seed-funding-to-redefine-surgical-visualization-with-ai-302417771.html
SOURCE vopemed
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advantech Unveils Qualcomm® Dragonwing™ IQ9-Based Solutions for Industrial Vision Intelligence
- Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
- Best Crypto To Buy Now: XRP and Solana ETF Inflows Accelerate as AlphaPepe Nears $2.5M Raised
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share